Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00243906 · ClinicalTrials.gov registry record · Phase 2

Interventional Management of Stroke (IMS) II Study

A Phase 2 study of Stroke, sponsored by University of Cincinnati.

Completed
Registry status
Phase 2
Development phase
81
Enrollment target
1
Study location

NCT00243906 is a Phase 2 study of Stroke that has completed, run by University of Cincinnati. The registered enrollment target is 81 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00243906, a Phase 2 study of Stroke, has completed, sponsored by University of Cincinnati.

COMPLETED
Registry status
Phase 2
Development phase
81 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to examine the effects of delivering intra-arterial recombinant tissue plasminogen activator (rt-PA) and ultrasound to the site of the blood clot blocking blood flow to the brain of stroke patients.

Conditions Studied

Stroke

Interventions

  • DRUG Recombinant tissue plasminogen activator
  • PROCEDURE Low-intensity ultrasound

Study Locations (1)

Ohio

  • University of Cincinnati - Cincinnati

Trial Details

FieldValue
Enrollment Target 81 participants
Start Date 2003-01
Est. Completion 2007-05
Phase Phase 2

Sponsor

University of Cincinnati

245 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00243906

The ClinicalTrials.gov registry entry for NCT00243906 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower). The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Stroke appearing as the primary indexed condition, and to 2 interventions - of which Recombinant tissue plasminogen activator is the first listed.

NCT00243906 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT00243906 about?

NCT00243906 is a clinical study titled "Interventional Management of Stroke (IMS) II Study". The purpose of this study is to examine the effects of delivering intra-arterial recombinant tissue plasminogen activator (rt-PA) and ultrasound to the site of the blood clot blocking blood flow to the brain of stroke patients.

What is the current status of trial NCT00243906?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2003-01. Estimated completion is 2007-05.

What conditions does trial NCT00243906 study?

This clinical trial studies the following conditions: Stroke.

What interventions are being tested in trial NCT00243906?

The interventions under investigation include: Recombinant tissue plasminogen activator (DRUG), Low-intensity ultrasound (PROCEDURE).

Who is sponsoring clinical trial NCT00243906?

This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00243906 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stroke

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.